Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Nov 5, 2025
Announced positive results from two pivotal Phase 3 Essential3 studies of ulixacaltamide HCl in essential tremor (ET); Pre-NDA meeting with FDA scheduled for Q4 2025
Read more at globenewswire.com270.98
+22.99 (+9.27%)
Find more stocks in the Stock Screener
PRAX Latest News and Analysis
